These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21538654)

  • 1. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.
    Alphs L; Morlock R; Coon C; Cazorla P; Szegedi A; Panagides J
    Int J Methods Psychiatr Res; 2011 Jun; 20(2):e31-7. PubMed ID: 21538654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
    Rekhi G; Alphs L; Ang MS; Lee J
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia.
    Garcia-Alvarez L; Garcia-Portilla MP; Saiz PA; Fonseca-Pedrero E; Bobes-Bascaran MT; Gomar J; Muñiz J; Bobes J
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(3):169-175. PubMed ID: 29628403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Chinese Version of the 16-Item Negative Symptom Assessment.
    Huang BJ; Wang Y; Miao Q; Yu X; Pu CC; Shi C
    Neuropsychiatr Dis Treat; 2020; 16():1113-1120. PubMed ID: 32440125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.
    Velligan DI; Alphs L; Lancaster S; Morlock R; Mintz J
    Psychiatry Res; 2009 Sep; 169(2):97-100. PubMed ID: 19664826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS.
    Preda A; Nguyen DD; Bustillo JR; Belger A; O'Leary DS; McEwen S; Ling S; Faziola L; Mathalon DH; Ford JM; Potkin SG; ; van Erp TGM
    Schizophr Res; 2018 Nov; 201():113-119. PubMed ID: 29935887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of the French version of the self-evaluation of negative symptoms (SNS)].
    Hervochon C; Bourgeois V; Rotharmel M; Duboc JB; Le Goff B; Quesada P; Campion D; Dollfus S; Guillin O
    Encephale; 2018 Dec; 44(6):512-516. PubMed ID: 29195803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Training novice raters on the Negative Symptom Assessment Scale.
    Axelrod BN; Alphs LD
    Schizophr Res; 1993 Mar; 9(1):25-8. PubMed ID: 8461268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
    Potkin SG; Phiri P; Szegedi A; Zhao J; Alphs L; Cazorla P
    Schizophr Res; 2013 Nov; 150(2-3):442-9. PubMed ID: 24075603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the 16-item Negative Symptom Assessment.
    Axelrod BN; Goldman RS; Alphs LD
    J Psychiatr Res; 1993; 27(3):253-8. PubMed ID: 7905033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study.
    Blanchard JJ; Bradshaw KR; Garcia CP; Nasrallah HA; Harvey PD; Casey D; Csoboth CT; Hudson JI; Julian L; Lentz E; Nuechterlein KH; Perkins DO; Skale TG; Snowden LR; Tandon R; Tek C; Velligan D; Vinogradov S; O'Gorman C
    Schizophr Res; 2017 Jul; 185():137-143. PubMed ID: 28087270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).
    Takeuchi H; Fervaha G; Lee J; Agid O; Remington G
    J Psychiatr Res; 2016 Sep; 80():87-92. PubMed ID: 27318892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the German version of the Clinical Assessment Interview for Negative Symptoms (CAINS).
    Engel M; Fritzsche A; Lincoln TM
    Psychiatry Res; 2014 Dec; 220(1-2):659-63. PubMed ID: 25138895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms.
    Phillips MR; Xiong W; Wang RW; Gao YH; Wang XQ; Zhang NP
    Acta Psychiatr Scand; 1991 Oct; 84(4):364-70. PubMed ID: 1746289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converting positive and negative symptom scores between PANSS and SAPS/SANS.
    van Erp TG; Preda A; Nguyen D; Faziola L; Turner J; Bustillo J; Belger A; Lim KO; McEwen S; Voyvodic J; Mathalon DH; Ford J; Potkin SG; Fbirn
    Schizophr Res; 2014 Jan; 152(1):289-94. PubMed ID: 24332632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
    Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.
    Sarró S; Dueñas RM; Ramírez N; Arranz B; Martínez R; Sánchez JM; González JM; Saló L; Miralles L; San L
    Schizophr Res; 2004 Jun; 68(2-3):349-56. PubMed ID: 15099616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Portuguese version of the Clinical Global Impression-Schizophrenia Scale: validation study.
    Lima MS; Soares BG; Paoliello G; Machado Vieira R; Martins CM; Mota Neto JI; Ferrão Y; Schirmer DA; Volpe FM
    Braz J Psychiatry; 2007 Sep; 29(3):246-9. PubMed ID: 17891261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.
    Vernon MK; Revicki DA; Awad AG; Dirani R; Panish J; Canuso CM; Grinspan A; Mannix S; Kalali AH
    Schizophr Res; 2010 May; 118(1-3):271-8. PubMed ID: 20172695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new rating scale for negative symptoms: the Motor-Affective-Social Scale.
    Trémeau F; Goggin M; Antonius D; Czobor P; Hill V; Citrome L
    Psychiatry Res; 2008 Sep; 160(3):346-55. PubMed ID: 18722021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.